Cigna Group
For the period ended Jun 30, 2025. Filed Jul 31, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Accounts Receivable, Net
Note 3 – Accounts Receivable, Net
The following amounts were included within Accounts receivable, net:
| (In millions) · June 30, 2025 · December 31, 2024 | |||
|---|---|---|---|
| Noninsurance customer receivables | $14,690 | $11,879 | |
| Pharmaceutical manufacturers receivables | 14,094 | 10,914 | |
| Insurance customer receivables | 1,606 | 3,199 | |
| Other receivables | 758 | 162 | |
| Total | $26,154 | ||
| Accounts receivable, net classified as assets of businesses held for sale | (1,927) | ||
| Total | $31,148 | $24,227 | |
These accounts receivable are reported net of our allowances of $6.9 billion and $5.0 billion as of June 30, 2025 and December 31, 2024, respectively. These allowances include contractual allowances for certain rebates receivable with pharmaceutical manufacturers and certain accounts receivable from third-party payors, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses, and other non-credit adjustments.
The Company's allowance for current expected credit losses was $388 million as of June 30, 2025 and $84 million as of December 31, 2024.
Accounts Receivable Factoring Facility
The Company maintains an uncommitted factoring facility (the "Facility") with a total capacity of $1.5 billion under which certain accounts receivable may be sold on a non-recourse basis to a financial institution. The Facility began in July 2023 with an initial term oftwo years, followed by automaticone-year renewal terms unless terminated by either party.
We sold manufacturer accounts receivable under the Facility of $1.3 billion for both the three months ended June 30, 2025 and 2024 and $2.7 billion and $3.2 billion for the six months ended June 30, 2025 and 2024, respectively. For the three and six months ended June 30, 2025 and 2024, factoring fees paid were not material. As of June 30, 2025, there were $1.0 billion of sold accounts receivable that have not been collected from manufacturers and have been removed from the Company's Consolidated Balance Sheets. As of December 31, 2024, all sold accounts receivable had been collected from manufacturers. As of June 30, 2025 and December 31, 2024, there were $297 million and $1.0 billion, respectively, of collections from manufacturers that have not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.